Tvardi Therapeutics (TVRD) Change in Accured Expenses: 2013-2017
Historic Change in Accured Expenses for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2017 value amounting to $1.2 million.
- Tvardi Therapeutics' Change in Accured Expenses fell 73.79% to $1.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.0 million, marking a year-over-year decrease of 148.32%. This contributed to the annual value of -$21.4 million for FY2024, which is 754.63% down from last year.
- Latest data reveals that Tvardi Therapeutics reported Change in Accured Expenses of $1.2 million as of Q4 2017, which was up 1,404.88% from $82,000 recorded in Q3 2017.
- Tvardi Therapeutics' 5-year Change in Accured Expenses high stood at $4.7 million for Q4 2016, and its period low was -$4.8 million during Q2 2017.
- In the last 3 years, Tvardi Therapeutics' Change in Accured Expenses had a median value of $634,000 in 2016 and averaged $546,667.
- Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 787.34% in 2015, then tumbled by 3,112.12% in 2016.
- Quarterly analysis of 5 years shows Tvardi Therapeutics' Change in Accured Expenses stood at -$548,000 in 2013, then slumped by 202.74% to -$1.7 million in 2014, then soared by 229.66% to $2.2 million in 2015, then skyrocketed by 118.92% to $4.7 million in 2016, then crashed by 73.79% to $1.2 million in 2017.
- Its Change in Accured Expenses stands at $1.2 million for Q4 2017, versus $82,000 for Q3 2017 and -$4.8 million for Q2 2017.